<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03330782</url>
  </required_header>
  <id_info>
    <org_study_id>AJIRB-MED-OBS-17-197</org_study_id>
    <nct_id>NCT03330782</nct_id>
  </id_info>
  <brief_title>Remifentanil for Preventing Propofol Injection Pain in Elderly Patients</brief_title>
  <official_title>Effect-site Concentration of Remifentanil for Preventing Propofol Injection Pain in Elderly Patients: A Comparison With Adult Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ajou University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ajou University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Elderly patients show different pharmacokinetic and pharmacodynamic variables and usually
      need smaller doses of anesthetic drugs than younger patients. The purpose of this study was
      to investigate the optimal effect-site concentration of remifentanil for preventing injection
      pain during propofol induction in elderly patients by the Dixon's up-and-down method.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 16, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Severity of propofol injection pain-4 point scale</measure>
    <time_frame>during 3 min after remifentanil and propofol infusion to reach the equilibrium of plasma and effect-site concentration</time_frame>
    <description>0 = no pain (negative response to questioning),
= mild pain (pain reported only in response to questioning without any behavioral signs),
= moderate pain (pain reported in response to questioning and accompanied by a behavioral signs or pain reported spontaneÂ¬ously without questioning),
= severe pain (vocal response accompanied by facial grimacing, arm withdrawal, or tears)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Drug Usage</condition>
  <arm_group>
    <arm_group_label>Elderly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Remifentanil was infused at predetermined effect-site concentration before propofol infusion in elderly patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adult</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Remifentanil was infused at predetermined effect-site concentration before propofol infusion in adult patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <description>Remifentanil was infused at predetermined effect-site concentration prior to propofol infusion (initial concentration: 3.0 ng/ml) in elderly patients (65-80 years)</description>
    <arm_group_label>Elderly</arm_group_label>
    <other_name>Ultiva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <description>Remifentanil was infused at predetermined effect-site concentration prior to propofol infusion (initial concentration: 3.0 ng/ml) in adult patients (20-60 years)</description>
    <arm_group_label>Adult</arm_group_label>
    <other_name>Ultiva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA physical status I or II undergoing general anesthesia

        Exclusion Criteria:

          -  neurologic disorder

          -  psychologic disorder

          -  vascular disorder

          -  patients with chronic pain

          -  difficulty in vascular access
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jong Yeop Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ajou University Hospital, Suwon, Gyeongki-do, South Korea, 443-721</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jong Yeop Kim</last_name>
    <phone>82-31-219-5574</phone>
    <email>kjyeop@ajou.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jong Yeop Kim</name>
      <address>
        <city>Suwon</city>
        <state>Gyeonggi-do</state>
        <zip>443-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jong Yeop Kim, MD</last_name>
      <phone>312195574</phone>
      <email>kjyeop@ajou.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2017</study_first_submitted>
  <study_first_submitted_qc>October 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>January 10, 2018</last_update_submitted>
  <last_update_submitted_qc>January 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ajou University School of Medicine</investigator_affiliation>
    <investigator_full_name>Jong Yeop Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>pain</keyword>
  <keyword>propofol</keyword>
  <keyword>remifentanil</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

